Hiring a Healthcare Branding Agency: A Step-by-Step Guide

Separating capacity extension from positioning correction

The first document a brand manager should write is not a creative brief. It is a one-page statement identifying whether the engagement fills a bandwidth gap or repairs a positioning problem. The two mandates draw different agencies, different scopes of work, and different measurement frameworks.

Capacity extension keeps the existing positioning, voice, and visual system intact and hires an agency to execute campaigns, landing pages, or admissions funnel assets at a volume the internal team cannot sustain. The evaluation criteria weight production speed, compliance turnaround, and channel fluency. Positioning correction is a different exercise. It touches the brand image antecedents that drive patient loyalty and satisfaction, including environment, communication, and responsiveness cues embedded in every touchpoint ¹. That scope requires an agency with research capability, stakeholder interview discipline, and the authority to challenge assumptions the internal team has stopped questioning.

Conflating the two produces predictable failures. A capacity-extension shop asked to reposition delivers polished executions of an outdated story. A positioning-correction firm hired for volume burns retainer hours on strategy work the organization did not budget for. Naming the mandate on paper, before vendors see the RFP, disciplines every downstream decision.

Aligning admissions, clinical, and legal stakeholders on scope

An RFP written by marketing alone underprices the engagement. Brand equity in a treatment center is built through patient satisfaction, service quality, and the work of medical staff as much as through creative output ⁷, which means the internal signatories should extend beyond the marketing function before the document leaves the building.

Three stakeholder groups warrant seats at the scoping table:

• Admissions leadership defines the funnel stages the agency’s work must feed and the call-handling behaviors the brand voice must match.
• Clinical leadership defines what the organization can honestly claim about modalities, staffing, and outcomes, given that brand image degrades quickly when messaging outruns the care experience ¹.
• Legal or compliance counsel defines the substantiation posture for outcome claims, testimonials, and pharmacotherapy references under FTC standards ⁹ and, where applicable, FDA risk-presentation rules ¹⁰.

The output of that alignment is a scope memo naming the claims the agency may make, the claims requiring review, and the claims off-limits without new evidence. Agencies pitch more sharply against that document, and the organization avoids paying for creative that fails legal review after the fact.

Mapping ethical risk in direct-to-consumer healthcare promotion

Compliance literacy is not a slide in the agency’s capabilities deck. It is the filter that determines whether a treatment center’s brand campaign survives contact with regulators, referral partners, and the clinical review board. Brand managers vetting agencies should start by naming the ethical risk categories the work will touch, then interrogate the agency on each one.

A 2024 scoping review of direct-to-consumer healthcare promotion mapped the concerns that recur across the literature:

• insufficient regulation appeared in 72% of publications
• questionable efficacy and quality in 70%
• safety and physical harms in 66%
• misleading advertising claims in 56%
• privacy in 34% ³

The distribution matters. It tells brand managers that regulatory posture and efficacy substantiation are not edge cases in the literature. They are the modal concerns, and any agency writing for a treatment center will face both in the first quarter of production.

Each category translates into a specific vetting question:

• Regulatory posture asks whether the agency knows which claims trigger FTC review versus FDA review versus state licensing scrutiny.
• Efficacy and quality asks whether the agency requires clinical sign-off before publishing outcome language.
• Safety asks how the agency handles messaging around modalities with known risk profiles, including medication-assisted treatment.
• Misleading claims asks how the agency stress-tests testimonial selection, before-and-after framing, and success-rate phrasing.
• Privacy asks how the agency’s targeting stack handles protected health information adjacencies in retargeting pixels, lookalike audiences, and CRM syncs ⁴.

An agency that cannot answer all five without pausing has not run this work before.

The substantiation stress-test: FTC, FDA, and AMA in one filter

The substantiation stress-test is a live exercise the brand manager runs during the pitch. It replaces the reference-check ritual with something the agency’s principals must perform in the room. The premise is simple: give the agency four claim types a treatment center routinely wants to make, and require them to describe the evidence tier and the risk-balance treatment each would need before publication.

The four claim types cover most of the surface area:

• Outcome claims include statements about completion rates, sobriety milestones, and reduced relapse.
• Modality efficacy claims describe what a specific therapy or program produces, such as trauma-focused work, dialectical behavior therapy, or contingency management.
• Staff credential claims describe licensure, specialization, and years of experience.
• Testimonial claims present patient or family narratives as evidence of what the organization delivers.

FTC guidance requires that labeling and advertising claims be truthful, not misleading, and substantiated by competent and reliable scientific evidence relevant to the specific claim ⁹. Outcome claims sit at the top of the evidence hierarchy and require internal data with documented methodology, not aggregated industry statistics repurposed as house numbers. Modality efficacy claims must be tied to the population and setting studied, not extrapolated to conditions the source research did not cover. Staff credential claims require current documentation on file. Testimonial claims require the customer’s typical experience or a clear and prominent disclosure of what typical results actually are.

Where the treatment center offers pharmacotherapy, FDA rules on risk-benefit balance in promotional material apply. Language communicating benefits and language communicating risks must be balanced and understandable to the consumer, with risk information presented with clarity and prominence rather than buried in footnotes ¹⁰. AMA advertising guidance layers on top: direct-to-consumer promotion should not encourage self-diagnosis and treatment, must identify the population at risk, and must comply with FDA rules ⁸.

Ethics for vulnerable populations: expectation framing and privacy

Substantiation covers what the campaign says. Ethics covers how the campaign behaves toward the people it reaches. Treatment center audiences include patients and families making decisions under acute distress, which raises the standard of care for both messaging tone and data practice.

The AMA ethics policy on advertising and publicity cautions against aggressive, high-pressure promotion when it creates unjustified medical expectations or is paired with deceptive claims ¹¹. That guidance rules out several tactics that surface routinely in behavioral health marketing: countdown urgency on admissions pages, guarantee language on outcomes, and testimonial-heavy hero sections that imply typicality without disclosure. Brand managers should ask the agency to walk through its position on each and reject the ones that trade regulatory exposure for a short-term conversion lift.

The expectation-framing risk is subtler. Advertising can shape how patients evaluate their experience before they receive care, which is a legitimate branding function when the underlying service quality matches the promise and a compliance problem when it does not. The counterbalance in the literature is that well-designed patient-facing communication can improve information-seeking behavior and produce more engaged interactions with clinicians, without eroding relationship quality ⁵. The distinction is craft, not category. Agencies that understand it produce messaging that raises comprehension without inflating expectation.

Privacy sits alongside expectation framing as the second front. Targeted digital campaigns raise informed-consent gaps and data-handling risks that generic marketing agencies underestimate, particularly around retargeting audiences built from health-adjacent site behavior ⁴. The vetting question is direct: how does the agency segment audiences without touching protected health information proxies, and what is its documented process when a platform’s audience-building feature crosses that line? A shrug at this question is disqualifying.

Reading a case study for evidence discipline, not visual craft

Every agency portfolio looks competent in a browser. The interrogation that matters happens beneath the visuals. Brand managers should ask the agency to walk through three case studies live and answer a fixed set of questions about each:

1. what claim was made in the hero section
2. what evidence file supported it
3. who signed off from the client’s clinical or legal side
4. what the agency changed after that review

The tell is whether the agency can produce the substantiation trail without hedging. A treatment center case study that reports an admissions lift without describing how outcome language was verified is a design portfolio, not a compliance-literate one. FTC guidance requires that each claim be supported by evidence relevant to the specific product and advertising context ⁹, which means the agency should be able to name the internal data or peer-reviewed source behind any outcome statement it published.

The second question is scope discipline. In competitive markets, hospital advertising spend has been associated with a 0.716% increase in top-box HCAHPS ratings and a 0.985% increase in “definitely recommend” responses for every 1% rise in ad-per-thousand expenditure, an effect the authors attribute to expectation framing rather than changes in care delivery ². An agency that cites this dynamic honestly, and describes how it avoids inflating perception past what the facility can deliver, is reading the literature the same way the brand manager should.

Interrogating brand voice against staff sincerity and rapport

Voice guidelines are the artifact most agencies over-index on and most treatment centers under-audit. The document reads well in isolation, then collapses on contact with the admissions call, the intake conversation, and the therapist’s first session. Brand image and customer satisfaction in healthcare track most strongly with staff sincerity, physician interactions, and rapport ⁶, which means the voice on the website has to be the voice the caller hears at 9:47 p.m. when they finally dial.

Brand managers should ask two portfolio questions in the pitch:

1. how did the agency source the voice for a prior treatment center engagement, and did that process include listening to recorded admissions calls or shadowing intake staff?
2. what changed in the client’s internal training after the brand voice was defined?

An agency that treats voice as a copywriting exercise decoupled from the human delivery has not built brand equity. It has built a mismatch that erodes trust the moment the prospect makes contact.

The follow-up is operational. The agency should describe how it hands the voice guide to admissions and clinical leadership, and what artifacts, call scripts, email templates, discharge language, it produces to keep expression consistent across the touchpoints patients actually use.